Am Fam Physician. 2024;110(3):315-317
Author disclosure: No relevant financial relationships.
KEY POINTS FOR PRACTICE
• High-intensity statin therapy is recommended for patients with chronic coronary disease, with the addition of ezetimibe or PCSK9 inhibitors for those with very high risk.
• SGLT-2 inhibitors and GLP-1 receptor agonists reduce cardiac events in patients with chronic coronary disease and type 2 diabetes or systolic heart failure, and they improve quality of life in those with heart failure and preserved ejection fraction.
• Daily colchicine reduces cardiac events and stroke in patients with chronic coronary disease and previous cardiac events.
From the AFP Editors
Approximately 20 million people in the United States live with chronic coronary disease. In 2023, the American College of Cardiology and American Heart Association released guidelines for management of chronic coronary disease, primarily for primary care physicians and cardiologists who provide care in the outpatient setting. Chronic coronary disease includes acute coronary syndrome, coronary revascularization, angina or ischemia equivalents, coronary disease diagnosed with coronary computed tomography angiography, or a positive stress test. Chronic coronary disease may be managed in the acute, postacute, or chronic setting.
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
